Guslandi Mario
Gastroenterology Unit, S.Raffaele University Hospital. Via Olgettina 60- Milano 20132, Italy.
Curr Pharm Des. 2014;20(28):4561-4. doi: 10.2174/13816128113196660724.
The concept that the gut microbiota plays a major role in the development of pouchitis in ulcerative colitis patients after restorative proctocolectomy with ileal pouch-anal anastomosis, is widely accepted and supported by a widespread use of some antibiotics (metronidazole and/or ciprofloxacin, rifaximin) to treat this condition. A possible, safer therapeutic alternative is represented by probiotics. To date the controlled studies addressing the possible efficacy of probiotic agents in the treatment of active pouchitis are few and inconclusive. By contrast the prophylactic use of a probiotic mixture (VSL #3) appears to be able to prevent development of pouchitis. The most convincing results have been observed in the maintenance of remission, where the probiotic mixture has been found, in most of the performed controlled trials, significantly effective in preventing pouchitis recurrence.
在溃疡性结肠炎患者行回肠储袋肛管吻合术的恢复性直肠结肠切除术后,肠道微生物群在袋炎发展中起主要作用这一概念已被广泛接受,并得到了一些抗生素(甲硝唑和/或环丙沙星、利福昔明)广泛用于治疗该疾病的支持。益生菌是一种可能更安全的治疗选择。迄今为止,针对益生菌制剂治疗活动性袋炎可能疗效的对照研究很少且尚无定论。相比之下,使用益生菌混合物(VSL#3)进行预防性治疗似乎能够预防袋炎的发生。在维持缓解方面观察到了最令人信服的结果,在大多数已进行的对照试验中,发现益生菌混合物在预防袋炎复发方面显著有效。